Skip to main content

Day: November 4, 2025

Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

– Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months–  – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49% ORR and mPFS 9.1 months in histology selective cohort of multiple late line, difficult to treat cancers provide further evidence of strong activity – – $225 million in gross proceeds from October 2025 financing extends cash runway into 2028 – BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today reported financial results for the third quarter ended September 30, 2025, and provided business highlights. “We are wrapping up 2025 with significant momentum,...

Continue reading

MKS Inc. Declares Quarterly Cash Dividend

ANDOVER, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) — MKS Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.22 per share, payable on December 5, 2025, to shareholders of record as of November 24, 2025.  Future dividend declarations, as well as the record and payment dates for such dividends, are subject to the final determination of the Company’s Board of Directors. About MKS Inc.MKS Inc. (NASDAQ: MKSI) enables technologies that transform our world. We deliver foundational technology solutions to leading edge semiconductor manufacturing, electronics and packaging, and specialty industrial applications. We apply our broad science and engineering capabilities to create instruments, subsystems, systems,...

Continue reading

LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform

Transaction Values WorkSimpli at $65 Million Enterprise Value; Supports LifeMD’s Strategic Focus on Scaling its Virtual Care and Pharmacy Businesses NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services and pharmacy, today announced the sale of its majority ownership interest in WorkSimpli Software LLC (“WorkSimpli”) in a transaction valuing WorkSimpli at an enterprise value of approximately $65 million. The buyer group was led by WorkSimpli founder and CEO Sean Fitzpatrick, with support from a private investment group. This transaction represents a key milestone in LifeMD’s strategic transformation, further positioning the Company as a pure-play healthcare company exclusively focused on expanding its virtual care and pharmacy offerings. Under the terms of the...

Continue reading

CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

– CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma – – Data supportive of CX-801’s mechanism of action and the ongoing Phase 1 combination study with KEYTRUDA® (pembrolizumab) – SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that initial translational data from the ongoing Phase 1 study of CX-801 in patients with advanced melanoma will be presented at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, being held in National Harbor, MD on November 7-9, 2025. “CX-801 was intentionally designed to unlock the powerful immune-modulating effects...

Continue reading

ECD Automotive Design’s Project Gravette Porsche Wins “Best in Show – European Modified” at the 2025 Festivals of Speed

The Fully Bespoke Porsche 993, Quickly Captured the Attention of Attendees and JudgesKISSIMMEE, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) — ECD Automotive Design, Inc. (“ECD” or the “Company”) (NASDAQ: ECDA), the world’s largest Land Rover and Jaguar restoration company known for its custom luxury builds, including bespoke Defenders, Range Rovers, Jaguar E-Types, Ford Mustangs and Toyota FJs, is proud to announce that its Project Gravette Porsche 993 earned Best in Show – European Modified Division at the 2025 Festivals of Speed, held October 26, 2025, at the Mission Resort + Club in Howey-in-the-Hills, Florida. The Project Gravette Porsche 993, ECD’s first Porsche 911 customization, made its pubic debut and quickly captured the attention of attendees and judges at the Festivals of Speed. “The Festivals of Speed is a premier showcase...

Continue reading

Fluent, Inc. to Announce Third Quarter 2025 Financial Results and Host Earnings Conference Call on November 13, 2025

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT) today announced that it will report financial results for the third quarter ended September 30, 2025, after the close of the U.S. financial markets on November 13, 2025. Fluent will host a conference call at 4:30 pm ET on the same day to discuss the results. The conference call can be accessed by phone after registering online at Fluent Conference Call or via audio at Audio Registration. The call and accompanying slide presentation will also be webcast simultaneously on the Fluent website on the Investor Relations Page. Please log in at least 15 minutes prior to the start of the call to ensure adequate time for any downloads that may be required. Following the call, a recorded replay of the webcast will be available for one year on Fluent’s Investor Relations...

Continue reading

Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager

CT-P72/ABP-102 poster selected as one of the Top 150 abstracts out of more than 1,300 submissions at SITC 2025  CT-P72/ABP-102 demonstrates potent and selective anti-tumor activity in HER2-high models, including Enhertu-resistant tumors Dual-affinity engineering reduces on-target, off-tumor activity and supports a favorable preclinical safety profile Data supports advancement toward clinical development in HER2-positive cancersBURLINGTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) — Abpro Corporation (Nasdaq: ABP) (“Abpro”) and Celltrion, Inc. (“Celltrion”) today announced that they will present new preclinical data for CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, being held November 6–10, 2025, at the Gaylord National Resort and...

Continue reading

Beyond Meat® Teams Up With Hard Rock Cafe to Bring the Latest Beyond Burger® to Fans Nationwide

Starting today, the iconic restaurant will offer the meaty, juicy Beyond Burger (IV) as a swap for any beef burger on its menuClassic Smashed Burger featuring Beyond BurgerThe Beyond Burger will be offered as a swap for any beef burger on Hard Rock Cafe’s core and kid’s menus, enabling guests to enjoy their go-to burger option with the added benefits of plant-based protein.Spicy Diablo Smashed Burger featuring Beyond BurgerWith a beefy flavor and high smoke point due to avocado oil, the latest Beyond Burger caramelizes and sizzles to perfection.EL SEGUNDO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Beyond Meat, Inc. (NASDAQ: BYND), a leader in plant-based meat, today announced the launch of its latest Beyond Burger (Beyond IV) at all Hard Rock Cafe North America company locations. The Beyond Burger will be offered...

Continue reading

La-Z-Boy Incorporated Announces Timing of Fiscal 2026 Second Quarter Earnings Release and Conference Call

MONROE, Mich., Nov. 04, 2025 (GLOBE NEWSWIRE) — La-Z-Boy Incorporated (NYSE: LZB) will report its Fiscal 2026 Second Quarter results for the period ended October 25, 2025 after the close of trading on the New York Stock Exchange on Tuesday, November 18, 2025, and will hold its quarterly investor conference call at 8:30 a.m. Eastern Time the following day, Wednesday, November 19, 2025. The conference call will be webcast live with corresponding slides at https://lazboy.gcs-web.com/. The dial-in phone number for the live conference call will be (888) 506-0062 for persons calling from within the U.S. or Canada, and the number for international callers will be (973) 528-0011. The participant access code is 973736. The conference call will be archived on the internet and accessible for one year. A telephone replay will be available...

Continue reading

Leviathan Gold Announces Receipt of Conditional Approval of the TSXV to Acquire Cura Exploration Botswana Corp. and its 100% Interest in Kalahari Copper and Uranium Exploration Portfolios, Botswana

VANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) — Leviathan Gold Ltd. (“Leviathan” or the “Company”) (LVX – TSXV, LVXFF – OTC, 0GP – FSE) is pleased to announce that it has received conditional approval of the TSX Venture Exchange (the “TSXV”) with respect to the previously announced proposed acquisition (the “Transaction”) of all of the issued and outstanding securities of Cura Exploration Botswana Corp. (“Cura”), further to its previous announcements on June 19, 2025, July 16, 2025, August 18, 2025, September 11, 2025 and October 20, 2025. Additionally, the Company announces that it has entered into an amending agreement dated October 31, 2025 (the “Amending Agreement”) to amend the terms of the amalgamation agreement dated September 11, 2025 (the “Amalgamation Agreement”) between the Company, Cura and 1555801 B.C....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.